Sign in Subscribe

immunotherapy

A collection of 61 issues

Case report: POLE mutation combined with dMMR/MSI

Skip to content The CRC Digest ▸ TREATMENT Case report: POLE mutation combined with dMMR/MSI (Am J Ther) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest — crcdigest.com

Case report: POLE-mutated, dMMR/MSI colorectal cancer

Skip to content The CRC Digest ▸ TREATMENT Case report: POLE-mutated, dMMR/MSI colorectal cancer (Am J Ther) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest — crcdigest.com

Dual checkpoint blockade compared to single-agent PD-1 in MSI-H metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Dual checkpoint blockade compared to single-agent PD-1 in MSI-H metastatic colorectal cancer A study examined dual CTLA-4/PD-1 blockade versus anti–PD-1 alone in MSI-H metastatic colorectal cancer, reporting early survival benefit and exploratory clinical predictors. (Clinical Colorectal Cancer) This content is

Disrupting KRAS-AGO2 interaction may sensitize KRAS-mutant CRC to therapy

Skip to content The CRC Digest Disrupting KRAS-AGO2 interaction may sensitize KRAS-mutant CRC to therapy Preclinical research developed peptide-gold nanoparticles that disrupt the interaction between mutated KRAS and AGO2, potentially sensitizing KRAS-mutated colorectal cancer to chemo-immunotherapy. (Apoptosis) This content is informational only and does not constitute medical advice. Always consult

Immunotherapy combinations tested in pMMR/MSS rectal cancer

Skip to content The CRC Digest Immunotherapy combinations tested in pMMR/MSS rectal cancer Meta-analysis evaluates immune checkpoint inhibitor-based neoadjuvant therapy for proficient mismatch repair and microsatellite stable locally advanced rectal tumors. (Clinical Colorectal Cancer) This content is informational only and does not constitute medical advice. Always consult your oncologist

Immune checkpoint inhibitors show promise in hard-to-treat rectal cancer subtype

Skip to content The CRC Digest ◆ TRIAL DATA Immune checkpoint inhibitors show promise in hard-to-treat rectal cancer subtype A new meta-analysis examined immune checkpoint inhibitor combinations as neoadjuvant therapy for locally advanced rectal cancer with proficient mismatch repair (pMMR) or microsatellite stable (MSS) tumors—a subtype that typically does not

Watch-and-Wait After Neoadjuvant Anti-PD-1 in dMMR/MSI-H CRC

Skip to content The CRC Digest Watch-and-Wait After Neoadjuvant Anti-PD-1 in dMMR/MSI-H CRC A multicenter real-world study from four Chinese hospitals evaluated long-term outcomes of a watch-and-wait strategy in stage II/III dMMR/MSI-H colorectal cancer patients who achieved endoscopic complete response after neoadjuvant anti-PD-1 monotherapy. (Frontiers in Immunology)

WNT Pathway Activation Drives Immune Evasion in BRAF-Mutant Colorectal Cancer

Skip to content The CRC Digest ◇ RESEARCH WNT Pathway Activation Drives Immune Evasion in BRAF-Mutant Colorectal Cancer Researchers using mouse models and organoids found that WNT pathway activation promotes malignant transformation and immune evasion in microsatellite-stable BRAF-mutant colorectal cancer. (Gastroenterology) This content is informational only and does not constitute medical

DPD Enzyme Pathway May Predict Immunotherapy Response in MSI-H CRC

Skip to content The CRC Digest ◇ RESEARCH DPD Enzyme Pathway May Predict Immunotherapy Response in MSI-H CRC A new study identifies the dihydropyrimidine dehydrogenase (DPD) metabolic pathway as the first predictor of immune checkpoint inhibitor efficacy in MSI-H tumors, potentially helping identify patients at risk for resistance. (Journal for ImmunoTherapy

Co-mutations in CREBBP/EP300 and POLE/POLD1 identify high tumor mutational burden in MSS colorectal cancer

Skip to content The CRC Digest Co-mutations in CREBBP/EP300 and POLE/POLD1 identify high tumor mutational burden in MSS colorectal cancer Analysis of over 30,000 tumors found that co-mutation of CREBBP/EP300 and POLE/POLD1 strongly predicted elevated tumor mutational burden in microsatellite-stable disease (median 155.9 vs.